Officials of the Center for Genetic Engineering and Biotechnology, As part of the Phase III clinical trial results of the vaccine, he reported that Abdala showed 100% efficacy against Covid.
They mention that it is in the prevention of both Severe systemic disease, eg death.
Member of the Political Bureau of the Party, Doctor of Science Marta Ayala Avila, General Director of CIGB, Chief Monitor of Clinical Studies of that institution, Doctor of Science Francisco Hernández Bernal, clarified that this means that none of the patients in the study progressed to severity.
This was done in a cohort of 153 patients, including 142 who received placebo and 11 who received Abdala. All were PCR positive patients. After developed signs and symptoms of the disease 14 days after vaccination of the third dose.
CIGB director pointed out that the effectiveness Evaluation was done on day 14 or more after the last dose.
When that time passes, the immune system expresses itself so that if someone does encounter the virus, it doesn’t get sick or become serious. Vaccine does not prevent infection But the disease is very mild and may not even transmit it from person to person.
Maria del Carmen Ricardo Cobas, principal investigator of the study, updated that the application of the second dose has already ended and is expected to start with the third in the middle of next week.
clinical trials in minors
Doctor of Science Verena Museo Gonzalez, Director of Clinical Research at CIGB, said that Abdala’s clinical trial In the pediatric population, between the ages of three and 18 years, in Camagüey, with the application of the first dose in 44 children aged 12 to 18 years.
In this first phase 88 volunteers and in the second phase around 592, Originally it is carried out in two health areas of Camagüey Municipality, but later it will be extended to seven areas.
In case of Phase I-II studies in convalescence with Abdala and MambisOneDoctor of Science Milidis Limonta Fernandez, Manager of the CIGB Anti-Covid Vaccine Project, He said those who have a negative PCR and two months after other volunteers have had the opportunity to receive a dose of either of the two candidates developed by CIGB could be included.
With regard to productive growth of Abdala, in the doc Jorge Valdes Hernandez, Deputy Director General of Science CIGB, He mentioned that more than nine million doses have been produced and distributed so far.
With information from Granma.